BackVirpax Pharmaceuticals Overview

Virpax Pharmaceuticals Selling, General & Admin

Selling, General & Admin expenses for VRPX.

Quarterly SG&A Expenses

$2.29M
↓ 36.24% YoY

As of Dec 31, 2024

Annual SG&A Expenses (TTM)

$6.26M
↓ 40.78% YoY

Trailing 12 months ending Dec 31, 2024

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin